Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TScan Therapeutics ( (TCRX) ) has provided an update.
On June 30, 2025, TScan Therapeutics held its annual meeting of stockholders, where two key proposals were voted upon. The stockholders elected Stephen Biggar, Gavin MacBeath, and Garry Nicholson as Class I directors for a three-year term and ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (TCRX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on TScan Therapeutics stock, see the TCRX Stock Forecast page.
Spark’s Take on TCRX Stock
According to Spark, TipRanks’ AI Analyst, TCRX is a Neutral.
TCRX’s overall stock score is mainly influenced by its financial challenges, including weak profitability and cash flow issues. Technical analysis suggests potential stabilization, but valuation remains a concern due to negative earnings. Strategic improvements are necessary to enhance financial health and investor confidence.
To see Spark’s full report on TCRX stock, click here.
More about TScan Therapeutics
TScan Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of T-cell receptor-engineered T-cell therapies for the treatment of cancer.
Average Trading Volume: 644,647
Technical Sentiment Signal: Sell
Current Market Cap: $80.92M
For detailed information about TCRX stock, go to TipRanks’ Stock Analysis page.